gorgevorgian

Stock to buy VRTX: Target +35%

看多
NASDAQ:VRTX   Vertex Pharmaceuticals Incorporated
Vertex stock is still actionable as it rebounds from the 10-week line. It has also blasted back above an alternative entry of 279.23.

The relative strength line has been spiking higher even as VRTX stock and the broader market struggled. The stock has retaken its 50-day moving average, an encouraging sign.

VRTX stock has soared more than 32% higher so far in 2022. This is especially impressive considering the broader market action.

Vertex is also highly profitable. As a result, VRTX stock has an EPS Rating of 99 out of a best-possible 99.

Earnings have grown by an average of 690% over the past three quarters. This easily beats CAN SLIM requirements.

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。